Cemiplimab, a Human PD-1 Monoclonal Antibody, Versus Chemotherapy in First-Line Treatment of Advanced NSCLC with PD-L1 >= 50%
View/ Open
Date
2019Author
Sezer, A.
Gogishvili, M.
Bentsion, D.
Kilickap, S.
Lowczak, A.
Gumus, M.
Gladkow, O.
Clingan, P.
Sriuranpong, V.
Rizvi, N.
Lee, S.
Li, S.
Snodgrass, P.
Navarro, M.
Lowy, I.
Rietschel, P.